AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12804730 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1A AAM
Number of subjects: 409
Study 10780867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 2.5, 5, or 10 mg/day for 1 year
Number of subjects: 88
Study 10780867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 8721381 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 10 days (first trial)
Number of subjects: 629
Study 8721381 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 21 days (second trial)
Number of subjects: 629
Study 8721381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in both trials)
Number of subjects: 629
Study 1815000 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal add progressive addition lenses (PALs)
Number of subjects: 29
Study 1815000 — intervention group
Group type: COMPARATOR
Intervention: Overplussed add progressive addition lenses (PALs)
Number of subjects: 29
Study 6689277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol alone (10 mg)
Number of subjects: 5
Study 6689277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone (25 mg)
Number of subjects: 5
Study 6689277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol and Hydrochlorothiazide in combination (Tenesor)
Number of subjects: 5
Study 31545480 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa_circ_0137606
Number of subjects: 0
Study 31545480 — intervention group
Group type: COMPARATOR
Intervention: High-grade BC
Number of subjects: 0
Study 30028922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 68
Study 30028922 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol (control group)
Number of subjects: 68
Study 26589633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-monthly BoNT-A injections
Number of subjects: 42
Study 26589633 — intervention group
Group type: COMPARATOR
Intervention: 12-monthly BoNT-A injections
Number of subjects: 42
Study 26589633 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for children with hemiplegia
Number of subjects: 42
Study 25456561 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to motivate physical activity over 12 months
Number of subjects: 242
Study 25456561 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 242
Study 22580592 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Early Warning Score (MEWS) calculated by anaesthetists before and after surgical procedure.
Number of subjects: 1082
Study 22580592 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients admitted before MEWS application).
Number of subjects: 1082
Study 20831131 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer cement
Number of subjects: 45
Study 20831131 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 45
Study 20831131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin cement
Number of subjects: 45
Study 18622315 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied at the time of tonsillectomy
Number of subjects: 70
Study 18622315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 70
Study 16564941 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose in dialysis fluid
Number of subjects: 44
Study 16564941 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose in dialysis fluid)
Number of subjects: 44
Study 16564941 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose in dialysis fluid (diabetic subgroup)
Number of subjects: 44
Study 16564941 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose in dialysis fluid, diabetic subgroup)
Number of subjects: 44
Study 12575969 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy with EDTA
Number of subjects: 47
Study 12575969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10588313 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 5 days
Number of subjects: 805
Study 10588313 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 10 days
Number of subjects: 805
Study 10588313 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg bd for 10 days
Number of subjects: 805
Study 8723851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (6000 U.kg‐1 before CPB and before declamping of aorta)
Number of subjects: 22
Study 8723851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 22
Study 8723851 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Group I)
Number of subjects: 22
Study 1929681 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 333
Study 1929681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 333
Study 1929681 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with bleeding episode
Number of subjects: 333
Study 6134481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 8 micrograms/kg
Number of subjects: 40
Study 6134481 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone or Althesin anaesthesia
Number of subjects: 40
Study 29223789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 18
Study 29223789 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 18
Study 28931194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular radiofrequency ablation tonsillectomy
Number of subjects: 22
Study 28931194 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular tonsillectomy
Number of subjects: 22
Study 25446228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 29
Study 25446228 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 29
Study 25446228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study 23212802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C > 2.04 mg/L
Number of subjects: 464
Study 23212802 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAM > 34 ng/mL
Number of subjects: 464
Study 23212802 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 464
Study 21548947 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (15 page)
Number of subjects: 1000
Study 21548947 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised reminder
Number of subjects: 1000
Study 21548947 — intervention group
Group type: COMPARATOR
Intervention: Long questionnaire (24 page)
Number of subjects: 1000
Study 21548947 — intervention group
Group type: COMPARATOR
Intervention: Reminder packs
Number of subjects: 1000
Study 21548947 — intervention group
Group type: COMPARATOR
Intervention: Reminder postcards
Number of subjects: 1000
Study 18420662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood glucose
Number of subjects: 184
Study 18420662 — intervention group
Group type: COMPARATOR
Intervention: No monitoring (control)
Number of subjects: 184
Study 16216315 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate 30 mg/m2 days 1, 15, and 22; vinblastine 3 mg/m2 days 2, 15, and 22; doxorubicin 30 mg/m2 day 2; cisplatin 70 mg/m2 day 2 q 4 weeks)
Number of subjects: 186
Study 16216315 — intervention group
Group type: COMPARATOR
Intervention: TC (cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1‐3 q 3 weeks)
Number of subjects: 186
Study 16216315 — intervention group
Group type: COMPARATOR
Intervention: C (cisplatin 50 mg/m2 q 3 weeks)
Number of subjects: 186
Study 16216315 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC, TC, and C
Number of subjects: 186
Study 12663724 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral etoposide (50 mg/m2/d)
Number of subjects: 58
Study 12663724 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily oral etoposide (50 mg/m2/d)
Number of subjects: 58
Study 12663724 — intervention group
Group type: COMPARATOR
Intervention: Once-daily vs twice-daily oral etoposide
Number of subjects: 58
Study 11382798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake of 0.8 g protein.kg(‐1).day(‐1) for 14 weeks
Number of subjects: 10
Study 9433633 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for testing association of genetic markers with disease in nuclear families
Number of subjects: 0
Study 8389572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dithiocarb (DDC)
Number of subjects: 64
Study 8389572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 64
Study 3538363 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 10 mg once daily for 4 weeks
Number of subjects: 19
Study 3538363 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg once daily for 4 weeks
Number of subjects: 19
Study 31280619 — intervention group
Group type: EXPERIMENTAL
Intervention: masitinib 4.5 mg/kg/d
Number of subjects: 394
Study 31280619 — intervention group
Group type: EXPERIMENTAL
Intervention: masitinib 3.0 mg/kg/d
Number of subjects: 394
Study 31280619 — intervention group
Group type: COMPARATOR
Intervention: riluzole + placebo
Number of subjects: 394
Study 31280619 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 394
Study 29661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive multiprobiotic 'Symbiter' (concentrated biomass of 14 probiotic bacteria genera Bifidobacterium, Lactobacillus, Lactococcus, Propionibacterium) for 8 weeks
Number of subjects: 53
Study 29661605 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 53
Study 29661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive multiprobiotic 'Symbiter'
Number of subjects: 53
Study 29661605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27455252 — intervention group
Group type: EXPERIMENTAL
Intervention: NIOR (+) diet for six months
Number of subjects: 171
Study 27455252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cust (+) diet for six months
Number of subjects: 171
Study 27455252 — intervention group
Group type: EXPERIMENTAL
Intervention: NIOR (−) diet for six months
Number of subjects: 171
Study 27455252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cust (−) diet for six months
Number of subjects: 171
Study 25041382 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.04 ms duration, starting from 0 mA in increments of 0.2 mA)
Number of subjects: 0
Study 25041382 — intervention group
Group type: COMPARATOR
Intervention: Pressure algometry
Number of subjects: 0
Study 23497788 — intervention group
Group type: EXPERIMENTAL
Intervention: DCS (50mg)
Number of subjects: 25
Study 23497788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21504954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (twice weekly for eight weeks)
Number of subjects: 30
Study 21504954 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 18004495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention with telephone checkups twice a week
Number of subjects: 88
Study 17075123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1692
Study 17075123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1692
Study 12639491 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Number of subjects: 0
Study 12639491 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Number of subjects: 0
Study 10957701 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and codeine suppository (60 mg codeine and 800 mg paracetamol) with standard premedication of intramuscular midazolam 0.08 mg/kg
Number of subjects: 90
Study 10957701 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository and midazolam
Number of subjects: 90
Study 8813040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 1102
Study 8813040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 1102
Study 8813040 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 1102
Study 1534961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day) for 6 weeks
Number of subjects: 0
Study 1534961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day) for 6 weeks
Number of subjects: 0
Study 3835918 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 155
Study 3835918 — intervention group
Group type: COMPARATOR
Intervention: Control non-adenoidectomy group
Number of subjects: 155
Study 29789100 — intervention group
Group type: EXPERIMENTAL
Intervention: TEXT ME text message support program
Number of subjects: 710
Study 29789100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 710
Study 27658890 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 74
Study 27658890 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study 23862643 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brainwave entrainment using binaural beats around 2-8 Hz for eight weeks
Number of subjects: 15
Study 23862643 — intervention group
Group type: COMPARATOR
Intervention: Control group with no auditory stimulation
Number of subjects: 15
Study 22658938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA (HMUFA) diet
Number of subjects: 84
Study 22658938 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 PUFA (LFHCCn-3)
Number of subjects: 84
Study 22658938 — intervention group
Group type: COMPARATOR
Intervention: Control oil (LFHCC)
Number of subjects: 84
Study 22658938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA (HSFA) diet
Number of subjects: 84
Study 19840889 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 36
Study 19840889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17681339 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 punctures on the left ovary and 12 on the right
Number of subjects: 96
Study 17681339 — intervention group
Group type: COMPARATOR
Intervention: 6 punctures on the right ovary and 12 on the left
Number of subjects: 96
Study 16327580 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a low dose of 0.5 mg/kg divided in two equal doses
Number of subjects: 118
Study 16327580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16327580 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 118
Study 12817764 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 12817764 — intervention group
Group type: EXPERIMENTAL
Intervention: Active control
Number of subjects: 0
Study 10802793 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 124
Study 10802793 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 124
Study 10802793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 10802793 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg and 10 mg
Number of subjects: 124
Study 8627080 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (0.1, 0.5, 1.0, or 2.0 mg/kg/day)
Number of subjects: 15
Study 1600040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined omeprazole (40 mg mane) and ranitidine (50 mg bolus followed by 12.5 mg/h)
Number of subjects: 12
Study 1600040 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg mane)
Number of subjects: 12
Study 1600040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg bolus followed by 12.5 mg/h)
Number of subjects: 12
Study 1600040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6198914 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (n = 23)
Number of subjects: 44
Study 6198914 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (n = 17)
Number of subjects: 44
Study 6198914 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 44
Study 6198914 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 44
Study 31759891 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (oral, nonpeptide gonadotropin-releasing hormone antagonist)
Number of subjects: 1686
Study 31013304 — intervention group
Group type: EXPERIMENTAL
Intervention: Variably-accelerated pattern search algorithm
Number of subjects: 0
Study 31013304 — intervention group
Group type: COMPARATOR
Intervention: Single variable optimization based on Den Hartog formula
Number of subjects: 0
Study 31013304 — intervention group
Group type: COMPARATOR
Intervention: Ergodic search method
Number of subjects: 0
Study 31013304 — intervention group
Group type: COMPARATOR
Intervention: Integer programming method
Number of subjects: 0
Study 31013304 — intervention group
Group type: COMPARATOR
Intervention: Traditional genetic algorithm
Number of subjects: 0
Study 31013304 — intervention group
Group type: COMPARATOR
Intervention: Traditional pattern search algorithm
Number of subjects: 0
Study 28056468 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Phonemic Awareness Curriculum (PAth to Literacy)
Number of subjects: 104
Study 28056468 — intervention group
Group type: COMPARATOR
Intervention: Vocabulary intervention (Story Friends)
Number of subjects: 104
Study 25306932 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skill Training (CST)
Number of subjects: 85
Study 25306932 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 85
Study 25306932 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 85
Study 23140112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-induction
Number of subjects: 97
Study 23140112 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 97
Study 21343146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-vectored HIV-1 vaccine
Number of subjects: 87
Study 21343146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-vectored HIV-1 vaccine (in subset with protective HLA types B27, B57, B58)
Number of subjects: 87
Study 21343146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 18222010 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant carboplatin and radiotherapy (50mg/m² IV infusion twice weekly, 54-72Gy, 30-40 fractions, 6-8 weeks)
Number of subjects: 144
Study 18222010 — intervention group
Group type: COMPARATOR
Intervention: Post-operative radiotherapy alone (54-72Gy, 30-40 fractions, 6-8 weeks)
Number of subjects: 144
Study 18222010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 17058295 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted Nissen fundoplication (RNF)
Number of subjects: 50
Study 17058295 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic Nissen fundoplication (LNF)
Number of subjects: 50
Study 12913045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-30 kg/m²)
Number of subjects: 10537
Study 12913045 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI >30 kg/m²)
Number of subjects: 10537
Study 12913045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and Obese
Number of subjects: 10537
Study 10733441 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol plus conventional therapy
Number of subjects: 111
Study 10733441 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 111
Study 8939323 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin B12 injections
Number of subjects: 2
Study 8939323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 2
Study 1413131 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of extended verbal information
Number of subjects: 151
Study 1413131 — intervention group
Group type: COMPARATOR
Intervention: Standard information of the department
Number of subjects: 151
Study 2856949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for one year)
Number of subjects: 291
Study 2856949 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 291
Study 29456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched thoracic spine manipulation
Number of subjects: 69
Study 29456442 — intervention group
Group type: COMPARATOR
Intervention: Unmatched thoracic spine manipulation
Number of subjects: 69
Study 27083430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (nucleotide/nucleoside analogues)
Number of subjects: 2557
Study 27083430 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (headache)
Number of subjects: 2557
Study 27083430 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (abdominal pain)
Number of subjects: 2557
Study 27083430 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (pharyngitis)
Number of subjects: 2557
Study 26181088 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (5 mg/day) plus conjugated equine estrogens (0.625 mg/day)
Number of subjects: 51
Study 26181088 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate plus placebo
Number of subjects: 51
Study 22327817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS) applied locally on extraction sockets
Number of subjects: 25
Study 22327817 — intervention group
Group type: COMPARATOR
Intervention: Direct packing with gauze (Control group)
Number of subjects: 25
Study 20554333 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreation and walking program (EG)
Number of subjects: 59